FDA Advice On Missing Data May Be To Avoid Missing It In The First Place
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
FDA officials respond to the recommendations of a National Research Council Panel on handling missing data in clinical trials, giving early indications of how FDA could be viewing a forthcoming guidance on the issue.